Coverage
-
June 04, 2014
The Federal Circuit on Tuesday declined bids by Roxane Laboratories Inc. and Actavis Inc. to review a panel's ruling that settlements allowing the companies to sell generic versions of Endo Pharmaceuticals Inc.'s painkiller Opana ER did not include licenses for later Opana patents.
2 other articles on this case.
View all »